Cytoreductive Surgery with the PlasmaJet Improved Quality-of-Life for Advanced Stage Ovarian Cancer Patients

Gatske M. Nieuwenhuyzen-de Boer*, Hanane Aamran, Caroline B. van den Berg, Sten Willemsen, Jurgen M.J. Piek, Nathalie Reesink-Peters, Marianne Maliepaard, Helena C. van Doorn, Suzanne Polinder, Heleen J. van Beekhuizen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

16 Downloads (Pure)

Abstract

Background: 

Knowledge of quality-of-life after cytoreductive surgery is important to counsel patients with advanced-stage epithelial ovarian cancer prior to surgery. The aim of this study was to determine whether the use of the PlasmaJet Surgical device during cytoreductive surgery has an effect on the quality-of-life of patients with advanced epithelial ovarian cancer. 

Methods: 

Data included in this prospective observational study were derived from the PlaComOv study, in which patients with advanced epithelial ovarian cancer were randomly assigned to have cytoreductive surgery with or without adjuvant use of the PlasmaJet. Quality-of-life was measured before surgery and one, six, 12, and 24 months after surgery with three questionnaires: the EORTC QLQ-C30, QLQ-OV28, and EQ-5D-5L. 

Results: 

Between 2018 and 2020, 326 patients were enrolled in the trial. The overall response rate was high, with the lowest response rate at 24 months of 77%. At 6 months, quality-of-life was higher in the intervention group (95%CI 0.009; 0.081, p = 0.045). At 12 months, quality-of-life was higher in the intervention group with fewer symptoms of fatigue, appetite loss, and diarrhea (95%CI 0.6; 10,0, p = 0.027); similarly, patients in the intervention group reported a better body image (95%CI −14.2; −3.0, p = 0.003) and a higher score on the visual analog scale (95%CI 1.99; 11.15, p = 0.005). At 24 months postoperatively, no further difference was found between the two groups except for pain (95%CI −12.9; −0.8, p = 0.027) and body image (95%CI −13.808; −0.733, p = 0.029). A higher quality-of-life in the intervention group was partially explained by the mediator ‘surgery outcome’. 

Conclusions: 

This study demonstrated knowledge of patients’ quality-of-life until two years after cytoreductive surgery. The use of the PlasmaJet Surgical device during cytoreductive surgery leads to a higher quality-of-life than conventional surgery with electrocoagulation alone. Even after adjustment for the mediator of surgical outcome, a higher quality-of-life was seen in patients who had surgery with the use of the PlasmaJet device.

Original languageEnglish
Article number3947
JournalCancers
Volume15
Issue number15
DOIs
Publication statusPublished - 3 Aug 2023

Bibliographical note

Funding Information:
The PlaComov study is funded by the Netherlands Organization for Health Research and Development (ZonMw), number 843001805. PlasmaSurgical and Medical Dynamics provide an in-kind subsidy for the loan and maintenance of the PlasmaJet systems during this research. Neither company was involved in the study design, and they were not involved in the collection, analysis, or interpretation of data, nor in the writing of this manuscript or in the decision to submit this manuscript for publication.

Publisher Copyright:
© 2023 by the authors.

Fingerprint

Dive into the research topics of 'Cytoreductive Surgery with the PlasmaJet Improved Quality-of-Life for Advanced Stage Ovarian Cancer Patients'. Together they form a unique fingerprint.

Cite this